Loading ABT detail
Loading ticker data...
Loading ABT detail
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders.
Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Chart data unavailable
On April 10, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company currently facing a challenging price performance with a year-to-date
A jury in Chicago on Thursday said Abbott Laboratories must pay $53 million in compensatory damages to a group of families that had accused the company of failing to warn that its formula for premature infants can cause a potentially deadly bowel disease, according to the Chicago Tribune.
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
With chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthy ABBOTT PARK, Ill., April 9, 2026 /PRNewswire/ -- Today, Abbott (NYSE: ABT), a global leader in chronic disease prevention, treatment and care, is releasing new survey findings highlighting a growing tension: 74% of U.S. adults believe most chronic diseases, such as diabetes or cardiovascular disease, are preventable, but only 1 in 4 feel very confident in knowing how to care for their health.
Abbott Laboratories has declined over 16% since my last review, which was previously rated a HOLD, as the valuation was a little rich. The acquisition of Exact Sciences adds a solid piece to a company with a long, proven track record. The segments were kind of a mixed bag in the most recent earnings report, and I'll be monitoring the struggling areas to see where they might go.
CCLA Investment Management decreased its holdings in Abbott Laboratories (NYSE: ABT) by 10.0% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 845,716 shares of the healthcare product maker's stock after selling 94,471 shares during the quarter. CCLA Investment Management's holdings in Abbott
Absolute Software Co. (ABT.TO) (TSE: ABT - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of C$0.00 and traded as high as C$18.26. Absolute Software Co. (ABT.TO) shares last traded at C$18.26, with a volume of 243 shares traded. Absolute Software
In the closing of the recent trading day, Abbott (ABT) stood at $103.56, denoting a +1.7% move from the preceding trading day.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories NYSE: ABT, a diversified healthcare powerhouse and a member of the elite dividend kings.
Cidel Asset Management Inc. reduced its stake in Abbott Laboratories (NYSE: ABT) by 4.1% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 322,225 shares of the healthcare product maker's stock after selling 13,616 shares during the quarter. Abbott
Savvy Advisors Inc. grew its stake in shares of Abbott Laboratories (NYSE: ABT) by 47.2% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,120 shares of the healthcare product maker's stock after buying an additional 9,658 shares during the quarter.
During a year when other healthcare stocks from the S&P500 have remained roughly flat, Abbott Laboratories (ABT) has struggled and lost ground by 22%. ABT which will announce Q1 earnings on the 16th of April is facing low revenue expectations for the quarter, but double-digit growth is expected in the following quarters. I highlight how ABT's financial profile and FCF base is solid enough to support continued annual dividend hikes where the yield is now at-year highs.
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
They are among the top players in their respective corners of the healthcare sector. Both should benefit in the long run as demand for medical products and services increases.
